Clinical meaning
The NP performs comprehensive well-woman assessments integrating menstrual cycle physiology, contraceptive counseling, menopause management, and cervical cancer screening. The menstrual cycle is regulated by the hypothalamic-pituitary-ovarian (HPO) axis: GnRH pulsatility from the hypothalamus stimulates anterior pituitary release of FSH and LH. The follicular phase (days 1-14) is characterized by FSH-driven follicular development and rising estradiol levels; the dominant follicle produces increasing estradiol that exerts negative feedback on FSH (suppressing competing follicles) and eventually positive feedback on LH, triggering the LH surge and ovulation at approximately day 14. The luteal phase (days 15-28) is characterized by the corpus luteum producing progesterone, which stabilizes the endometrium for potential implantation, increases basal body temperature, and thickens cervical mucus. Without fertilization, corpus luteum regression causes progesterone withdrawal and menstruation. Well-woman exam components include age-appropriate screening (cervical cytology, mammography, bone density), blood pressure measurement, BMI calculation, pelvic examination when indicated, clinical breast exam, and assessment of mental health including depression and intimate partner violence screening. Contraceptive counseling uses a tiered effectiveness approach: Tier 1 (most effective, less than 1% failure) includes IUDs and implants (LARC methods); Tier 2 includes injectables, pills, patches, and rings; Tier 3 includes barrier methods and fertility awareness. Menopause is diagnosed after 12 consecutive months of amenorrhea without other pathological cause, typically occurring at mean age 51. Genitourinary syndrome of menopause (GSM) includes vulvovaginal atrophy, dyspareunia, and urinary symptoms from estrogen deficiency.